An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate

被引：0
|
作者：
T Leguay
V Desplat
V Lagarde
G Marit
J Reiffers
F-X Mahon
机构：
[1] Laboratoire hématopoïèse leucémique et cible thérapeutique INSERM E0217,
[2] Université Victor Segalen Bordeaux II,undefined
[3] Service des Maladies du Sang,undefined
[4] Hôpital du Haut-Lévèque,undefined
来源：
Leukemia | 2005年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1671 / 1673
页数：2
相关论文
共 50 条
  • [41] Mutations in the BCR/ABL kinase encoding the resistance to imatinib mesylate do not modify the sensitivity to genotoxic treatment.
    Bargaoanu, Milene
    Skorski, Tomasz
    BLOOD, 2006, 108 (11) : 622A - 623A
  • [42] Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
    Pfeifer, H.
    Lange, T.
    Wystub, S.
    Wassmann, B.
    Maier, J.
    Binckebanck, A.
    Giagounidis, A.
    Stelljes, M.
    Schmalzing, M.
    Duehrsen, U.
    Wunderle, L.
    Serve, H.
    Brueck, P.
    Schmidt, A.
    Hoelzer, D.
    Ottmann, O. G.
    LEUKEMIA, 2012, 26 (07) : 1475 - 1481
  • [43] Serial Analysis of BCR-ABL Kinase Domain Mutations Prior to and During Imatinib Treatment for Newly Diagnosed and Recurrent BCR-ABL Positive Acute Lymphoblastic Leukemia.
    Pfeifer, Heike
    Wystub, Sylvia
    Wassmann, Barbara
    Maier, Jaqueline
    Lange, Thoralf
    Hochhaus, Andreas
    Hoelzer, Dieter
    Ottmann, Oliver
    BLOOD, 2009, 114 (22) : 806 - 806
  • [44] Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
    H Pfeifer
    T Lange
    S Wystub
    B Wassmann
    J Maier
    A Binckebanck
    A Giagounidis
    M Stelljes
    M Schmalzing
    U Dührsen
    L Wunderle
    H Serve
    P Brück
    A Schmidt
    D Hoelzer
    O G Ottmann
    Leukemia, 2012, 26 : 1475 - 1481
  • [45] ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts - Reply
    Laudadio, Jennifer
    Press, Richard D.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2008, 10 (05): : 476 - 476
  • [46] Management of imatinib mesylate-resistances induced by BCR-ABL mutations in chronic myelogenous leukemia
    Nicolini, Franck-Emmanuel
    Ducastelle, Sophie
    Corm, Selim
    HEMATOLOGIE, 2007, 13 (06): : 457 - 464
  • [47] BCR-ABL independent clones in Imatinib mesylate resistant chronic myelogenous leukemia patients.
    Donato, NJ
    Wu, JY
    Stapley, J
    Hui, L
    Arlinghaus, RB
    Aggarwal, B
    Albitar, M
    Pathak, S
    Hayes, KJ
    Talpaz, M
    BLOOD, 2002, 100 (11) : 371A - 371A
  • [48] Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate
    Hardling, M
    Wei, Y
    Palmqvist, L
    Swolin, B
    Stockelberg, D
    Gustavsson, B
    Ekeland-Sjöberg, K
    Wadenvik, H
    Ricksten, A
    MEDICAL ONCOLOGY, 2004, 21 (04) : 349 - 358
  • [49] Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate
    Mats Hardling
    Yuan Wei
    Lars Palmqvist
    Birgitta Swolin
    Dick Stockelberg
    Bengt Gustavsson
    Kerstin Ekeland-Sjöberg
    Hans Wadenvik
    Anne Ricksten
    Medical Oncology, 2004, 21 : 349 - 358
  • [50] Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts
    Pratibha Sharma
    Lalit Kumar
    Sujata Mohanty
    Vinod Kochupillai
    Annals of Hematology, 2010, 89 : 241 - 247
12345